Physician profile
Danielle M Simons
NPI 1811362130
$6,618.85
in general payments reported to CMS, 2019-2025
20 companies · $1,121 in 2025
The $1,121 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $829 · 2022: $1,153 · 2023: $1,746 · 2024: $1,769 · 2025: $1,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,296 · Education: $340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,296.27 |
| Education | $340.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,804.89 | 2021-2025 | |
| Janssen Biotech, INC. | $972.07 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Sun Pharmaceutical Industries INC. | $604.24 | 2021-2025 | Ilumya, Blu-U |
| Lilly USA, LLC | $589.85 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $587.14 | 2021-2025 | |
| Genzyme Corporation | $346.02 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $328.60 | 2023-2025 | Sotyktu |
| Pfizer INC. | $266.55 | 2021-2025 | |
| Ucb, INC. | $210.91 | 2022-2025 | Cimzia, Bimzelx |
| Regeneron Healthcare Solutions, INC. | $197.05 | 2021-2025 | Dupixent, Libtayo |
| Amgen INC. | $160.24 | 2022-2024 | Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.10 | 2024 | Spevigo |
| Incyte Corporation | $95.48 | 2022-2025 | Opzelura |
| Galderma Laboratories, L.P. | $91.46 | 2021-2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $56.37 | 2023-2025 | Zoryve |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $50.06 | 2025 | Anzupgo |
| Almirall LLC | $46.40 | 2022-2023 | Seysara |
| Verrica Pharmaceuticals INC. | $44.97 | 2024 | Ycanth |
| Dermavant Sciences, INC. | $42.28 | 2023-2024 | Vtama |
| Merz North America, INC. | $17.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Simons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.